Navigation Links
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Date:12/18/2007

who require chemotherapy. There are presently no drugs approved to treat PS2 patients with advanced NSCLC. Current treatments for this group of patients are poorly tolerated, with most tolerating a median of two doses of chemotherapy and experiencing disease progression on average within six weeks. Most physicians will utilize single-agent gemcitabine or vinorelbine to treat these frail patients. Current treatments also have limited effectiveness, with median survival ranging from only ten weeks for single-agent treatment to just over 17 weeks for combination therapies.

About the STELLAR 4 Trial

The STELLAR 4 phase III clinical trial tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of poor performance status (PS2) patients with NSCLC. While the STELLAR 4 trial missed its primary endpoints of significant improvement in overall survival, it did demonstrate significant reductions in many of the clinically relevant toxicities associated with gemcitabine or vinorelbine. Based on the clinical benefit of lower severe toxicities, reduced use of hematopoietic growth factors and transfusions, enhanced convenience, and reduced medical resource utilization and associated costs, in 2006 CTI received a positive opinion from the Scientific Advice Working Party (SAWP) of the EMEA that a switch from the superiority endpoint to a non-inferiority endpoint is feasible if adequate justification is provided in the marketing application.

About XYOTAX(TM)

XYOTAX(TM) (paclitaxel poliglumex, CT-2103) is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unl
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... MIAMI (PRWEB) March 02, 2015 ... a newly formed alliance with Shenzhen HANK Bioengineering ... M.D., Ph.D. The alliance will establish a stem ... Guangdong Province, China in September 2015. , Shenzhen ... by Zhang, an award-winning scientist, microbiologist and virologist, ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: ... release disseminated this morning by PR Web, and redistributed ... release states that Immunovaccine has entered into a co-development ... did not originate from Immunovaccine and there is no ... Please note that all official statements by Immunovaccine ...
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their offering. ... 9002-07-7) aims at providing comprehensive data on Trypsin globally and ... , North America , Latin ... close attention to Trypsin This report focuses on ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2
... managed, with the help of an advanced X-ray flash, to ... that has been recognised by the journal Science . ... home to one of the world,s most advanced particle accelerators, ... and study life,s tiniest components: atoms, molecules and proteins. ...
... PLYMOUTH MEETING, Pa. , May 10 /PRNewswire-Asia-FirstCall/ -- ... announced,financial results for the first quarter ended March 31, 2010 . ... ... was a,quarter of successful management transition at Sunstone. We replaced senior,managers including ...
... Fla. , May 10 Dyadic International, Inc. ... today that its President and Chief Executive Officer, Mark ... Renshaw 6th Annual Global Healthcare Conference in London, England ... 11:05 a.m. local time ( 6:05 a.m. EDT ). ...
Cached Biology Technology:BMP Sunstone Reports First Quarter 2010 Financial Results 2BMP Sunstone Reports First Quarter 2010 Financial Results 3BMP Sunstone Reports First Quarter 2010 Financial Results 4BMP Sunstone Reports First Quarter 2010 Financial Results 5BMP Sunstone Reports First Quarter 2010 Financial Results 6BMP Sunstone Reports First Quarter 2010 Financial Results 7BMP Sunstone Reports First Quarter 2010 Financial Results 8BMP Sunstone Reports First Quarter 2010 Financial Results 9BMP Sunstone Reports First Quarter 2010 Financial Results 10BMP Sunstone Reports First Quarter 2010 Financial Results 11BMP Sunstone Reports First Quarter 2010 Financial Results 12Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference 2
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... F. Laurance, senior staff scientist at the Smithsonian Tropical ... the Institute and Biodiversity Chair at the H. John ... have won the coveted 2008 BBVA Foundation Frontiers of ... 30 Jan. 2009 in Madrid, Spain. , ...
... deposited iron in the Southern Ocean has filled in ... in locking atmospheric carbon dioxide (CO2) in the ocean. ... Raymond Pollard of the National Oceanography Centre, Southampton, and ... Hole Oceanographic Institution (WHOI), found that natural iron fertilization ...
... many studies refuting the claim of a link between vaccines ... issue of Clinical Infectious Diseases and now available ... epidemiological and biological studies refute these claims. "When one ... springs up to take its place," said study author Paul ...
Cached Biology News:Smithsonian scientists receive coveted BBVA Ecology and Conservation Award 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 2Ocean islands fuel productivity and carbon sequestration through natural iron fertilization 3Vaccines and autism: Many hypotheses, but no correlation 2
... automated microplate strip washer for 96- and 384-well ... strip washing capability, the Columbus combines high flexibility ... , Features ,Key features ... or 16 channels, crosswise aspiration, overflow and bottom ...
... solution for all plate washing needs in both ... ,The PW 384 provides an excellent solution for ... Discovery (Assay development, Screening or Lead Optimization) and ... ,The PW 384 has set a standard for ...
... Protein:Protein Interaction Reagent A powerful new ... gained traction as an in vitro method ... of publications feature the exclusive Pierce ProFound ... a variety of issues relating to protein ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: